Gujarat Terce Laboratories Ltd. (BSE: 524314) is a Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹27 Cr, it ranks #4,398 by market cap among the 6,189 Indian listed companies on FinBizNet, and #57 of 63 in Pharmaceuticals. At ₹34.13 (as of 26 Oct 2026), the share price is 33.1% below its 52-week high of ₹51.00 and 17.7% above its 52-week low of ₹29.00. The share price is down 36.4% over one year and down 2.2% over three months.
| Current Price | ₹34.13 |
|---|---|
| Market Cap | ₹27 Cr |
| BSE Code | 524314 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 11.7 |
| Return on Equity | 27.14% |
| Return on Assets | 8.77% |
| 52-Week Range | ₹29.00 – ₹51.00 |
| 1-Year Price Change | -36.4% |
| 3-Month Price Change | -2.2% |
| Beta (1Y) | 0.19 |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.gujaratterce.in |
| Revenue | ₹9 Cr |
|---|---|
| Net Profit | ₹-0 Cr |
| Net Margin | -2.0% |
| EPS (Basic) | ₹0.23 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Gujarat Terce Laboratories Limited develops, manufactures, markets, and distributes medicines and healthcare products in India and internationally. The company offers generic pharmaceutical for therapeutic areas, such as antibiotics, respiratory, nutraceuticals, gastrology, gynecology, pain therapy, and ayurvedic. It provides tablets, capsules, oral liquids, ointments, and injections under the Acolate, Tynol, Resplash, Ferlit, Z-Oxi, Vitfol, Thyter, Aziter, Codimol, Cefter, and Terflora brands. Gujarat Terce Laboratories Limited was incorporated in 1985 and is based in Ahmedabad, India.
1. Pharmaceutical-This segment manufactures and markets medical and pharmaceutical preparations. It offers branded and generic formulations covering various therapeutic areas, such as antibiotics, respiratory, nutraceuticals, gastrointestinal, anti-fungal, and others. 2. Metal-This segment manufactures copper sulphate. 3. Corporate-0 4. Segment Adjustment-0
1. Pharmaceutical-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹53,132 Cr | 34.2 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,028 Cr | 38.9 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹33,581 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹25,398 Cr | -77.7 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹23,578 Cr | 93 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹16,891 Cr | 26.4 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹16,525 Cr | 22.9 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,199 Cr | 24.2 | 18.07% | ₹873 Cr | -30.8% |
| Gujarat Terce Laboratories Ltd. | ₹27 Cr | 11.7 | 27.14% | ₹9 Cr | -36.4% |
Listed by market capitalisation. Ratios are shown for context only.
Gujarat Terce Laboratories Ltd. is trading at ₹34.13, with a market capitalisation of ₹27 Cr.
Gujarat Terce Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Gujarat Terce Laboratories Ltd. has a P/E of 11.7 and a return on equity of 27.14%.
Gujarat Terce Laboratories Ltd. is listed on the BSE under the scrip code 524314.
Gujarat Terce Laboratories Ltd.'s share price is down 36.4% over one year and down 2.2% over three months. Its 52-week range is ₹29.00 to ₹51.00.
In Q1 FY27, Gujarat Terce Laboratories Ltd. reported revenue of ₹9 Cr and net profit of ₹-0 Cr, with basic EPS of ₹0.23 (standalone, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.